Correlation Between Seres Therapeutics and Biodexa Pharmaceticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Seres Therapeutics and Biodexa Pharmaceticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Seres Therapeutics and Biodexa Pharmaceticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Seres Therapeutics and Biodexa Pharmaceticals, you can compare the effects of market volatilities on Seres Therapeutics and Biodexa Pharmaceticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Seres Therapeutics with a short position of Biodexa Pharmaceticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Seres Therapeutics and Biodexa Pharmaceticals.

Diversification Opportunities for Seres Therapeutics and Biodexa Pharmaceticals

0.49
  Correlation Coefficient

Very weak diversification

The 3 months correlation between Seres and Biodexa is 0.49. Overlapping area represents the amount of risk that can be diversified away by holding Seres Therapeutics and Biodexa Pharmaceticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Biodexa Pharmaceticals and Seres Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Seres Therapeutics are associated (or correlated) with Biodexa Pharmaceticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Biodexa Pharmaceticals has no effect on the direction of Seres Therapeutics i.e., Seres Therapeutics and Biodexa Pharmaceticals go up and down completely randomly.

Pair Corralation between Seres Therapeutics and Biodexa Pharmaceticals

Given the investment horizon of 90 days Seres Therapeutics is expected to generate 0.57 times more return on investment than Biodexa Pharmaceticals. However, Seres Therapeutics is 1.76 times less risky than Biodexa Pharmaceticals. It trades about 0.06 of its potential returns per unit of risk. Biodexa Pharmaceticals is currently generating about -0.03 per unit of risk. If you would invest  82.00  in Seres Therapeutics on September 4, 2024 and sell it today you would earn a total of  11.00  from holding Seres Therapeutics or generate 13.41% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthWeak
Accuracy98.44%
ValuesDaily Returns

Seres Therapeutics  vs.  Biodexa Pharmaceticals

 Performance 
       Timeline  
Seres Therapeutics 

Risk-Adjusted Performance

4 of 100

 
Weak
 
Strong
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Seres Therapeutics are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. Despite somewhat conflicting basic indicators, Seres Therapeutics sustained solid returns over the last few months and may actually be approaching a breakup point.
Biodexa Pharmaceticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Biodexa Pharmaceticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of conflicting performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Seres Therapeutics and Biodexa Pharmaceticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Seres Therapeutics and Biodexa Pharmaceticals

The main advantage of trading using opposite Seres Therapeutics and Biodexa Pharmaceticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Seres Therapeutics position performs unexpectedly, Biodexa Pharmaceticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Biodexa Pharmaceticals will offset losses from the drop in Biodexa Pharmaceticals' long position.
The idea behind Seres Therapeutics and Biodexa Pharmaceticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.

Other Complementary Tools

Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings